Can a peptide supplement sharpen a foggy mind? A new randomized trial of N-PEP-12 says something interesting happened at the 90-day mark. It also comes with caveats you should read before you buy anything.
The Quick Take
- Who was studied: 276 adults aged 50-75 with subjective cognitive complaints (SCCs) and no clinically significant cognitive impairment.
- What they took: placebo, N-PEP-12 at 45 mg, or N-PEP-12 at 90 mg.
- How long: assessments at baseline, 30, 90 and 180 days.
- Headline result: a significant group-by-visit interaction (p = 0.003) across three primary attention outcomes, meaning the groups diverged over time.
- The catch: the main effect of treatment arm was not significant (p = 0.133), and the endpoint-by-endpoint findings are labeled exploratory by the authors.
What Is N-PEP-12?
The paper, published in Nutrients (2026) by Chira and colleagues, describes N-PEP-12 as a peptide-based nutritional supplement with potential neuroprotective effects. The abstract does not spell out the peptide's composition or mechanism, so I won't speculate here. The authors note that evidence for benefits in healthy adults with SCCs has been limited, which is the gap this trial tries to fill.
SCCs are the "where did I put my keys" or "why can't I focus" experiences that are common in midlife and later. They can sit alongside changes in stress, mood, sleep and quality of life. They may also reflect early cognitive change, which is why researchers target this group.
How the Trial Worked
This was a prospective, randomized, double-blind, placebo-controlled trial, the standard design for supplement research. Participants were split across placebo, 45 mg and 90 mg arms.
Primary outcomes were measures from the Test of Attentional Performance. Secondary outcomes included:
- WAIS-IV Digit Span Forward and Backward (a working-memory measure)
- Perceived stress
- Mood
- Sleep quality
- The EQ-5D-5L visual analog scale (self-rated health)
The Numbers That Matter
The three primary attention outcomes were analyzed together in a multivariate repeated-measures model. The results:
| Test | Result |
|---|---|
| Group-by-visit interaction | p = 0.003 (significant) |
| Effect of visit | p < 0.001 (significant) |
| Main effect of treatment arm | p = 0.133 (not significant) |
The authors read this as a time-dependent treatment effect: the active groups' trajectories differed from placebo as the weeks went on. A non-significant main effect means you can't simply say "N-PEP-12 beats placebo overall." The signal is about how scores changed across visits.
The significant result also came from a sensitivity analysis population in which missing data were imputed under assumptions least favorable to the active arms. That is a deliberately conservative approach, and it is a point in the study's favor.
The 90-Day Findings
In exploratory endpoint-specific comparisons at 90 days, both N-PEP-12 groups showed greater improvements than placebo in:
- Alertness
- Attention omissions (missed targets on attention tasks)
- Memory omissions
Digit Span Forward and Backward scores also improved. The abstract reports these as improvements without giving effect sizes, so I can't quote magnitudes here. The full text is the place to look for those.
The authors' conclusion links N-PEP-12 to improvements in attention, working memory and mental wellbeing. Note the word associated, which is more cautious than "causes."
The Extension Phase: Interesting, Not Proof
After the controlled period, there was an uncontrolled extension in which everyone received active treatment. Participants who started on placebo showed comparable improvements after switching to N-PEP-12 90 mg.
This is encouraging for consistency, but without a control group it can't separate the supplement's effect from practice effects, expectation or natural fluctuation. The authors themselves describe these observations as exploratory.
Safety
Adverse events were infrequent and similarly distributed across groups. That is reassuring for a 180-day study, but the abstract doesn't detail event types, so check the full paper if you take medications or have health conditions.
Practical Takeaways
Doses used: 45 mg and 90 mg of N-PEP-12 per day. Both showed greater 90-day improvements than placebo on the exploratory endpoints. The abstract doesn't declare one dose superior, and the extension used 90 mg.
Timing: the abstract doesn't say whether participants took it in the morning or evening, or with food. No timing recommendation is supported by what I could see. Follow the product label and the full paper's methods.
Time horizon: the benefits were described as time-dependent and highlighted at 90 days. If you try it, don't expect an overnight effect.
Who it might suit: the evidence applies to generally healthy adults aged 50-75 with subjective cognitive complaints and no clinically significant impairment. It does not tell us about people with diagnosed mild cognitive impairment or dementia, younger adults, or people seeking a performance boost with no complaints.
Limitations to Keep in Mind
- Exploratory endpoints. The authors flag the endpoint-specific findings as exploratory, so they are hypothesis-generating rather than confirmatory.
- No significant main treatment effect (p = 0.133).
- Uncontrolled extension. It can't establish causation.
- Subjective population. SCCs are self-reported and vary widely.
- Unclear mechanism. The abstract gives no detail on how the peptide might work.
- Funding and conflicts of interest. These aren't stated in the abstract. With supplement trials, it's worth checking the full paper.
- Needs replication. The authors say the results support further investigation, not clinical recommendation.
Bottom Line
N-PEP-12 is a promising candidate rather than a proven brain booster. The time-dependent signal, the conservative imputation and the low rate of side effects are encouraging. The non-significant main effect and exploratory framing of the specific endpoints mean the results warrant larger confirmatory trials before anyone calls it a cognitive solution. If you're considering it, talk to a clinician, especially if memory complaints are new or worsening, since those deserve proper evaluation.
Study: Chira et al. Impact of N-PEP-12 Supplementation on Attentional Performance and Mental Wellbeing in Healthy Adults with Subjective Cognitive Complaints: A Randomized, Placebo-Controlled Trial. Nutrients, 2026. DOI: 10.3390/nu18162739 | PubMed 42654319
